Insight

Bruna Pellini: Are all immune checkpoint inhibitors the same?

Bruna Pellini/LinkedIn

Nov 7, 2024, 13:12

Bruna Pellini: Are all immune checkpoint inhibitors the same?

Bruna Pellini, Assistant Professor at the University of South Florida shared her recent article on X:

“Are all immune checkpoint inhibitors (ICIs) the same?

Our hot off the press pub on SCLC suggests they are NOT.”

“In a recent retrospective study Zou et al compared the efficacy and safety of atezolizumab vs. durvalumab + chemo for pts with ES-SCLC in China and found patients treated with Durvalumab had a mOS of 22 mo vs. 10 mo with atezolizumab. This motivated us to conduct a similar study at Moffitt Cancer Center.”

“In our retrospective study in Extensive Stage SCLC 101 patients were included and patients treated with Durvalumab had a superior OS of 14.7 months vs. 11.6 months with Atezolizumab.”

“PFS and PFS2 were the not statistically different between the two groups and atezolizumab was associated with a higher incidence of ICI-related AEs.”

“Prospective studies and head-to-head trials are warranted to confirm if any differences in efficacy or toxicities exist between these two agents since two retrospective studies in different countries demonstrated similar results!

Congrats to our mentee Megan Vince that led this study!”

Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer.

Authors: Megan Vince, et al.

Bruna Pellini is an Assistant Professor at the University of South Florida and an Assistant Member in the Department of Thoracic Oncology at Moffitt Cancer Center. Her research centers on the use of liquid biopsies to monitor treatment response, detect minimal residual disease (MRD), and integrate these techniques into clinical trials.